Anti-thymocyte globulin therapy induced a spurious increase of fibrinogen degradation products in hypoplastic myelodysplastic syndrome.
Yahata
Yuriko
Y
Isobe
Yasushi
Y
Sasaki
Makoto
M
Oshimi
Kazuo
K
Sugimoto
Koichi
K
D000910:Antibodies, Heterophile / Q000097:blood; D000961:Antilymphocyte Serum / Q000494:pharmacology* / Q000627:therapeutic use; D005189:False Positive Reactions; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis*; D006801:Humans; D007118:Immunoassay / Q000592:standards; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000473:pathology*
D000910:Antibodies, Heterophile; D000961:Antilymphocyte Serum; D005338:Fibrin Fibrinogen Degradation Products